NeuraLight Completes PALOMA Study Demonstrating Superior Eye-Movement Biomarkers for Parkinson's Disease Progression Tracking
核心洞察
NeuraLight completed PALOMA, a 12-month multicenter study with 300 Parkinson's patients, representing one of the largest longitudinal trials using eye-movement biomarkers to track disease progression.
The study demonstrated that NeuraLight's eye-movement biomarkers correlate significantly with standard clinical assessments like MDS-UPDRS and MoCA, with 10x more sensitivity than current gold standards.
The platform's 10-minute tablet-based assessment offers a more objective and scalable approach to monitoring Parkinson's progression compared to traditional clinical tools.
NeuraLight has completed PALOMA, a groundbreaking 12-month multicenter longitudinal study that enrolled 300 participants with idiopathic Parkinson's disease (搜索) across clinical sites in the US, Portugal, Spain, and the UK. The study represents one of the largest longitudinal clinical trials using eye-movement biomarkers to follow disease progression in Parkinson's patients over time.
Revolutionary Biomarker Technology Shows Superior Sensitivity
The PALOMA study (Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease (搜索)) focused on comparing NeuraLight's eye-movement based biomarkers with standard clinical assessments including MDS-UPDRS and MoCA. The company's software-based platform delivers biomarkers with 10x more sensitivity than MDS-UPDRS, the current gold standard for measuring Parkinson's progression.
"PALOMA is an important step toward more objective, scalable ways to track Parkinson's disease (搜索) progression in real-world clinical research," said Dr. Michelle Tosin, leading principal investigator of the trial and head assistant professor in the Department of Neurological Sciences at Rush University Medical Center in Chicago. "By comparing NeuraLight's precise eye-movement measures with standard clinical outcome assessments (COAs), such as MDS-UPDRS and MoCA, we can capture consistent signs of change over time."
Clinical Validation and Patient Acceptance
The study enrolled patients with idiopathic Parkinson's disease (搜索) (Hoehn & Yahr 1-2; 0-5 years since diagnosis) and evaluated correlations between oculometric measures and clinical assessments over 12 months. The primary aim was to assess whether oculometric measures can detect deterioration earlier than currently available clinical tools.
Dr. Tosin emphasized the practical advantages of the platform: "The NeuraLight platform is also user-friendly and practical to deploy. In our experience, patients tolerate the short examination well, which supports repeat use over time and makes this approach well-suited for multicenter studies. These results suggest NeuraLight's oculometric biomarkers can help measure progression in clinical trials with greater sensitivity and repeatability."
Significant Clinical Correlations Demonstrated
Initial PALOMA data presented by Dr. Tosin at the 2024 MDS International Congress demonstrated that NeuraLight's anti-saccade-derived eye-movement biomarkers correlate moderately and significantly with MoCA cognitive scores in Parkinson's disease (搜索). A comprehensive paper detailing the study's full results is currently under peer review.
The NeuraLight platform's 10-minute assessment, conducted on a standard tablet, represents a significant advancement in neurological assessment technology. According to CEO and co-founder Edmund Ben-Ami, "This international study provides further evidence of NeuraLight's ability to deliver validated neuroprogression biomarkers that bring unprecedented sensitivity to neurological assessment. For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson's disease (搜索) over time, unlocking a new standard for neurological drug development."
Broader Clinical Applications and Future Impact
The platform is currently deployed in clinical partnerships across the globe, spanning over 1,200 patients with Parkinson's disease (搜索), ALS (搜索), MS (搜索), and Huntington's disease (搜索), as well as in multiple commercial pharmaceutical trials. The completion of PALOMA follows NeuraLight's recent announcement of its Scientific Advisory Board members, which include multiple globally recognized scientific leaders and Nobel laureates.
The PALOMA trial (NCT05862649) was conducted across international academic centers, demonstrating the scalability and reproducibility of the eye-movement biomarker approach across diverse clinical settings and patient populations.